Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
Open Access
- 19 October 2020
- Vol. 8 (4), 616
- https://doi.org/10.3390/vaccines8040616
Abstract
Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited therapeutic options. One of these options is immune checkpoint inhibitors. The aim of this study is to comprehensively review the efficacy and safety of immune checkpoint inhibitors for patients with HCC.This publication has 92 references indexed in Scilit:
- Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II TrialsPLOS ONE, 2012
- Hepatocellular CarcinomaThe New England Journal of Medicine, 2011
- HCC and angiogenesis: possible targets and future directionsNature Reviews Clinical Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Intestinal Tolerance Is Converted to Autoimmune Enteritis upon PD-1 Ligand BlockadeThe Journal of Immunology, 2009
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular CarcinomaClinical Cancer Research, 2009
- SorafenibDrugs, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular CarcinomaJournal of Clinical Oncology, 2008